Simulations Plus (NASDAQ:SLP) Releases Earnings Results, Beats Expectations By $0.02 EPS

Simulations Plus (NASDAQ:SLP) announced its quarterly earnings data on Wednesday. The technology company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02, Briefing.com reports. The firm had revenue of $18.70 million during the quarter, compared to analyst estimates of $19.73 million. Simulations Plus had a net margin of 14.36% and a return on equity of 7.80%. Simulations Plus’s revenue was up 19.9% on a year-over-year basis. During the same period last year, the firm posted $0.18 EPS. Simulations Plus updated its FY25 guidance to $1.07 to $1.20 EPS and its FY 2025 guidance to 1.070-1.200 EPS.

Simulations Plus Stock Performance

Shares of NASDAQ:SLP traded down $0.28 during midday trading on Friday, reaching $30.68. 276,597 shares of the company’s stock traded hands, compared to its average volume of 130,076. The company has a fifty day simple moving average of $33.08 and a two-hundred day simple moving average of $40.63. Simulations Plus has a 1 year low of $29.37 and a 1 year high of $51.22. The company has a market cap of $613.91 million, a P/E ratio of 63.92 and a beta of 0.69.

Analysts Set New Price Targets

SLP has been the subject of a number of research analyst reports. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a report on Thursday. KeyCorp initiated coverage on Simulations Plus in a research note on Monday, July 29th. They set an “overweight” rating and a $47.00 price target on the stock. Craig Hallum restated a “buy” rating and issued a $56.00 price objective on shares of Simulations Plus in a research note on Wednesday, July 3rd. BTIG Research dropped their target price on Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, JMP Securities started coverage on shares of Simulations Plus in a research report on Tuesday, July 16th. They set a “market perform” rating for the company. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $54.50.

Insiders Place Their Bets

In other news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $35.18, for a total value of $703,600.00. Following the sale, the director now owns 3,501,592 shares in the company, valued at $123,186,006.56. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders sold 60,750 shares of company stock worth $2,145,055. Company insiders own 20.90% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.